share_log

B of A Securities Downgrades Kymera Therapeutics to Neutral, Lowers Price Target to $30

Benzinga ·  Jan 3 09:23

B of A Securities analyst Geoff Meacham downgrades Kymera Therapeutics (NASDAQ:KYMR) from Buy to Neutral and lowers the price target from $45 to $30.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment